ArticleJournal of ovarian research2026
Two cycles of chemotherapy modulate itaconic acid levels via ATF3/TET2/NF-κB pathways in ovarian cancer among Han Chinese women.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe metabolic rationale chemotherapy cycles after debulking surgery in ovarian cancer (OC) remain unclear. This prospective cohort was aimed to define metabolic changes induced by chemotherapy and assess longitudinal effects.
methodsMetabolites between treatment-naïve OC patients (n = 26) and age-matched healthy controls (n = 30) were identified by gas chromatography-mass spectrometry (GC-MS). Chemotherapy-related signaling molecules were quantified via enzyme-linked immunosorbent assay.
resultsOur analysis identified 38 differentially expressed metabolites, including critical intermediates in the tricarboxylic acid (TCA) cycle and revealed significant reductions in five TCA cycle intermediates, namely itaconic acid, citric acid, fumaric acid, cis-aconitic acid, and malic acid, in OC patients compared to controls. Following the first chemotherapy cycle, absolute quantification of 128 metabolites was performed, with targeted metabolomic analysis of TCA cycle intermediates revealing an increase in levels of itaconic acid prior to the second chemotherapy cycle. Remarkably, after two chemotherapy cycles, itaconic acid concentrations normalized to levels comparable to those in healthy controls, suggesting metabolic recovery. Furthermore, significant inverse correlations were observed between human epididymis protein 4 (HE4) levels and the concentrations of the five TCA cycle intermediates, highlighting the potential of these metabolites as biomarkers. Mechanistic studies revealed that two cycles of chemotherapy restored metabolic homeostasis, normalizing itaconic acid levels and reactivating the Activating transcription factor 3 (ATF3)/ten-eleven translocation 2 (TET2)/NF-kappaB (NF-κB) signaling pathway to levels seen in healthy participants.
conclusionsOur pilot data suggest that two chemotherapy cycles may help restore metabolic homeostasis in patients who have undergone complete cytoreduction. These findings provide preliminary insights into chemotherapy-induced metabolic reprogramming and warrant further investigation in larger, outcome-driven studies.
trial registrationClinicalTrials.gov ID: ChiCTR2300069160.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.